Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study

Trial Profile

Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Phase III Study to Investigate the Efficacy, Safety, and Tolerability of 2 Different Doses of IgPro20 (Subcutaneous Immunoglobulin) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - the PATH Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Immune globulin (Primary) ; Immune globulin
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy
  • Focus Registrational; Therapeutic Use
  • Acronyms PATH
  • Sponsors CSL Behring
  • Most Recent Events

    • 20 Jun 2019 According to a CSL Behring media release, new analysis from the PATH study will be presented at the 2019 annual meeting of the Peripheral Nerve Society (PNS, 22nd-26th June,in Genoa, Italy).
    • 26 Mar 2019 According to the CSL Behring media release, based on the data from the PATH and PRIMA trials, Japan's Ministry of Health, Labour and Welfare has approved Privigen [human normal immunoglobulin, 10% liquid, intravenous], ready-to-use therapy for acute and maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy.
    • 26 Mar 2019 According to the CSL Behring media release, based on the data from this study and its extension study, Japan's Ministry of Health, Labour and Welfare has approved Hizentra [human normal immunoglobulin, 20%, subcutaneous] for the maintenance treatment of chronic inflammatory demyelinating polyradiculoneuropathy in Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top